2nd Advance-HTA Capacity Building Workshop

Santiago, Chile, 9-10 September 2015


Rational

In recent years HTA has become part of the agenda of Latin American countries. Many countries have implemented legislation and institutional changes related to HTA and its application to support the decision-making process. Yet, there is a considerable heterogeneity both across but also within countries and many issues remain to be resolved.

Latin American countries are increasingly embracing HTA activities and are looking towards Europe for adaptation, knowledge and information to update their capacity and skills. The Advance-HTA Capacity Building Workshop is therefore an opportunity to build HTA capacity, outline the options available for decision-makers and debate the actions required for this purpose, tailor-made for the needs of the countries in this region.


Objectives

  • Undertake HTA capacity building in Latin America
  • Present the HTA methodological advances developed by the Advance HTA Consortium
  • Discuss the relevance of such methodological advances with local participants from Latin America
  • Discuss future developments in HTA and their policy implications
  • Foster international collaboration and create a network for exchange of expertise


The workshop took place in Santiago, Chile, on 9-10 September 2015. It was organized by Advance-HTA with additional support from the Escuela Andaluza de Salud Publica (EASP) and the Pan-American Health Organization (PAHO).

The workshop was attended by 64 participants, mainly policy makers working in public institutions such as Ministries of Health, Health Insurance Funds, Social Security Institutes and HTA Agencies. In total, 13 countries were represented: Argentina, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Ecuador, Mexico, Paraguay, Peru, Uruguay and USA.


Agenda and Resources

The 2-day workshop included 6 sessions:

  • Assessing Value for Money
  • Value Assessment in Health Technology
  • Using Alternative Methods to Assess Value of New Medical Technologies
  • HTA and Rare Disease: Assessing the Societal Value of Orphan Drugs
  • HTA and Medical Devices
  • Strengthening and Implementing HTA in Emerging Settings

Click here to access the full program.


All presentations delivered during the workshop are provided below:

How Can Value for Money Be Assessed?

Why Do Some Countries Approve a Cancer Drug and Others Don’t?

State of the Art: Methods of Value Assessment – Challenges and Limitations

Value Assessment: Building Value Propositions from an HTA Perspective

Using Multiple Criteria Decision Analysis: Conceptual framework and model

MCDA application: Empirical evidence from an experimental case study on metastatic colorectal cancer

HTA and Rare Disease: Assessing the Societal Value of Orphan Drugs

Evaluation of Medical Devices: How Is It Different? Current Practices Across European HTA Agencies

Approaching the Evaluation of Different Types of Medical Devices Based on a New Taxonomic Model

The Importance of HTA in Emerging Settings - The REDETSA Experience

HTA in Emerging Settings – Mapping Exercise and Toolbox


Feedback

Based on feedback received from participants, the workshop was a success in terms of quality of speakers, program’s structure and content, and general workshop’s administration. In fact, more than 70% stated the workshop met their expectations and 100% would recommend the workshop to colleagues.

“I was very satisfied with this workshop. The exchange of experience was excellent.”

“Congratulations this was an excellent workshop!”

“ There is a lot of work to do sharing experiences between countries - this is a great opportunity.”


Acronym ADVANCE_HTA
Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.